Condition: Sporadic and Familial Amyotrophic Lateral Sclerosis · Sponsor: Peking University Third Hospital
This is a randomized double-blind controlled exploratory clinical study to evaluate the efficacy and safety of FB1006 in the treatment of amyotrophic lateral sclerosis (ALS) patients.
This description comes directly from the study's public registry record.
Sun Can · +86-10-82265791 · scdoctor@qq.com
Always discuss trial participation with your own doctor first.
| Peking University Third Hospital | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05923905